Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Dasatinib

Dasatinib 100 mg administered once daily per oral route for 28 consecutive days

DRUG

Leuprolide Acetate (LHRH Analogue)

Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).

PROCEDURE

Radical Prostatectomy

Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.

Trial Locations (6)

23502

Virginia Oncology Associates, Norfolk

32610

University of Florida, Gainesville

46202

Indiana University Simon Cancer Center, Indianapolis

60637

University of Chicago, Chicago

61401

Medical & Surgical Specialists, LLC, Galesburg

85054

Mayo Clinic Hospital, Scottsdale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Noah Hahn, M.D.

OTHER

NCT00860158 - Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter